Product Description
Mechanisms of Action: BCL2 Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: European Medicines Agency
Approved Indications: None
Known Adverse Events: None
Company: Genta
Company Location: BERKELEY HEIGHTS NJ 07922
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Lymphoid Leukemia|Melanoma|Acute Myeloid Leukemia
Phase 2: Prostate Cancer|Kidney Cancer|Head and Neck Cancer|Adenocarcinoma|Hepatocellular Carcinoma|Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma|Bladder Cancer|Carcinoma, Merkel Cell|Leukemia, Plasma Cell|Intraocular Lymphoma|Ovarian Cancer|Colorectal Cancer|Lung Cancer|Breast Cancer|Mantle-Cell Lymphoma|Follicular Lymphoma|Esophageal Cancer|Waldenstrom Macroglobulinemia|Neuroendocrine Carcinoma|Chronic Lymphoid Leukemia|Extranodal NK-T-Cell Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Large-Cell Immunoblastic Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Male Breast Cancer|Plasmablastic Lymphoma|Liver Cancer|Lymphomatoid Granulomatosis|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Cutaneous Lymphoma|Adult T-Cell Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Renal Cell Carcinoma|B-Cell Marginal Zone Lymphoma|Burkitt Lymphoma|Melanoma|Gastrointestinal Cancer|Small Cell Lung Cancer|Squamous Cell Carcinoma|Gastrointestinal Stromal Tumors|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia
Phase 1: Oncology Solid Tumor Unspecified|Lymphoma, Non-Hodgkin|T-Cell Cutaneous Lymphoma|Diffuse Large B-Cell Lymphoma|Burkitt Lymphoma|B-Cell Marginal Zone Lymphoma|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Adult T-Cell Leukemia-Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Mantle-Cell Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Follicular Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Plasma Cell|Plasmablastic Lymphoma|Large-Cell Immunoblastic Lymphoma|Kidney Diseases|Melanoma|Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT01200342 | P2 |
Terminated |
Melanoma |
2013-09-01 |
|
0462-07-FB | P1 |
Terminated |
Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma |
2012-10-09 |
|
AGENDA | P3 |
Completed |
Melanoma |
2011-05-01 |
|
2007-003340-30 | P3 |
Completed |
Melanoma |
2011-04-28 |